New partnership helps holistic care app reach more people with rheumatoid arthritis

Digital healthcare specialist Daman has signed a new partnership agreement that will see its innovative RheumaBuddy app reach more people with rheumatoid arthritis (RA).

Daman has signed the agreement with pharmaceutical companies Gilead Sciences and Galapagos to extend the reach of its RheumaBuddy app to support people with RA. The partnership agreement runs until September 15th 2021 with the possibility of extension.

According to the National Rheumatoid Arthritis Society (NRAS), one percent of the population in the UK has RA, equating to over 400,000 people.

To help people with RA self-manage the disease and track their symptoms, Daman developed the RheumaBuddy app as an adjunct to traditional care.

According to the company, the app provides continuous, cost-effective, and timely support to patients with rheumatoid arthritis, which improves their quality of life.

“There is a huge unmet need among RA patients to give more holistic care offerings. The partnership enables us to take important steps in the direction – to the benefit of patients and society,” said Andreas Dam, CEO at Daman.

NRAS has been working alongside Daman for years and promoting the use of the RheumaBuddy app to people with RA in the UK.

Clare Jacklin, NRAS CEO, commented: “RheumaBuddy is a really valuable addition to the ‘patients’ resource toolkit’. The app encourages and promotes better disease self-management and empowers individuals to track and understand their disease progress in a very user-friendly application.”

Daman says that during the next six months, new features will be added to RheumaBuddy, inspired by co-creation with patients, including The Good Consultation, which helps patients and healthcare professionals collaborate better, and My Plan & Goal, which provides guidance and support for developing healthy habits to cope with RA.